Sign in
Enrolling by invitationPhase 4

Tests weight-loss drugs in postmenopausal women with obesity

Studies semaglutide or tirzepatide's effects on weight, movement and blood vessels in women with obesity.

Key facts

Who runs it
Mayo Clinic
Where
Jacksonville, United StatesSee the site
Trial code
Registry title
Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women
Status
Enrolling by invitation
Phase
Phase 4
People taking part
30 people, planned
Started
1 May 2025
Expected to end
31 Mar 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • semaglutide or tirzepatide
  • Lifestyle modification intervention
Record updated
20 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for postmenopausal women aged 46-60 years who live with obesity (BMI of 30 kg/m2 or more). It studies weight loss with semaglutide or tirzepatide.

Age
46-60 years
Sex
Women only
Disease stage
Obesity, with a BMI of 30 kg/m2 or more. Menopause means no periods for at least 12 months, or removal of both ovaries.
Earlier treatment
Cannot have used menopausal hormone therapy, or other anti-obesity medication in the past 3 months. Cannot have had bariatric surgery.

Main reasons for not taking part

  • Diabetes
  • Cardiovascular disease
  • Early or premature menopause, or menopause caused by chemicals
  • Kidney function that is too low (GFR 29 or lower)
  • Personal or family history of medullary thyroid cancer

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Postmenopausal women (with menopause defined as the cessation of menstrual periods for at least 12 months or history of bilateral oophorecomy)
  • Age 46-60 years old
  • BMI ≥ 30 kg/m2

Who cannot take part

  • Past or current use of menopausal hormone therapy
  • >5% change in weight during the 3 months prior to screening
  • Other anti-obesity medication use within the past 3 months
  • History of chemically induced menopause
  • Diabetes
  • Cardiovascular disease
  • Uncontrolled co-morbidities including inflammatory, autoimmune, infectious, hepatic, gastrointestinal, malignant, or psychiatric disease
  • History of bariatric surgery
  • History of malignant neoplasms within the past 5 years prior to screening
  • Personal or family history of medullary thyroid cancer
  • Impaired renal function (GFR ≤29)
  • Early or premature menopause
  • Thyroid-stimulating hormone ≥7 with low free T4
  • Elevated blood pressure (>170/>95)
  • Current use of supplements known to affect weight
  • Wheelchair bound
  • Vision loss

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 46 and 60 years old?

Where in United States

  • Mayo Clinic in FloridaJacksonville, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

In postmenopausal women, obesity increases the risk of physical function decline, premature aging, and vascular dysfunction. Semaglutide and tirzepatide are potent obesity medications. The goal is to determine the effect of weight loss induced by the new generation of GLP-1 receptor agonists on physical function, aging biomarkers, and vascular function in postmenopausal women with obesity.

The 2 groups in the trial

  • Weight loss medication and standard lifestyle interventionTreatment being tested

    Subjects will receive tirzepatide or semaglutide in combination with a standard lifestyle intervention.

    Treatment: semaglutide or tirzepatide and Lifestyle modification intervention

  • Standard lifestyle intervention onlyExisting treatment, for comparison

    Subjects will receive standard of care lifestyle intervention only.

    Treatment: Lifestyle modification intervention

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women
Plain-language title
Tests weight-loss drugs in postmenopausal women with obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07057310, who can take part
Record updated
20 July 2026